Ivabradin Al (Ivabradine)

Ivabradine selectively blocks the hyperpolarization‑activated cyclic nucleotide‑gated (HCN) channels that generate the funny (If) current in the sinoatrial node. Inhibition of this inward Na⁺/K⁺ mixed current slows spontaneous depolarisation, producing a pure heart‑rate‑lowering (chronotropic) effect while leaving myocardial contractility and ventricular repolarisation unchanged.

The appropriate dose of ivabradine is determined by the prescribing physician based on the patient’s clinical condition, heart‑rate target, renal and hepatic function, and concomitant medications. Dosage adjustments are made according to therapeutic response and tolerability, and the medication is taken orally as directed on the prescription label.

The safety of ivabradine during pregnancy and lactation has not been established; it is classified as pregnancy category unknown. It should be used only if the potential maternal benefit justifies any possible risk to the fetus, and breastfeeding mothers should consult their healthcare provider before initiating therapy.

To request Ivabradin Al, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India supplies hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain requirements) and assistance with import documentation.

Both ivabradine and beta‑blockers lower heart rate, but ivabradine acts selectively on the If current without influencing β‑adrenergic receptors, myocardial contractility, or bronchial tone. This makes it useful when beta‑blockers are contraindicated, not tolerated, or when additional heart‑rate reduction is needed beyond what beta‑blockers provide.

Store tablets at ambient temperature, preferably below 25 °C, in the original container to protect them from moisture and light. Keep the product out of reach of children and do not use after the expiry date printed on the packaging.

Ivabradin Al is taken orally, usually with meals to improve absorption. The tablet should be swallowed whole with a glass of water and not crushed or chewed. Dosing frequency and timing are prescribed by the treating physician.

The most serious adverse events include symptomatic bradycardia, atrial fibrillation, severe hypotension, and allergic reactions such as rash or angioedema. Patients should be monitored for these events, especially when initiating therapy or adjusting dose, and seek immediate medical attention if they experience fainting, palpitations, or signs of an allergic reaction.

Ivabradine is contraindicated in patients with severe hepatic impairment, acute decompensated heart failure, sick sinus syndrome, sino‑atrial block, or resting heart rate below 50 beats per minute. It should also be avoided in individuals taking strong CYP3A4 inhibitors unless dose adjustments and close monitoring are implemented.